Anbenitamab has potential for research in HER2-positive metastatic breast cancer (MBC); it blocks both ligand-dependent and ligand-independent HER2 signaling pathways and mediates potent antibody-dependent cell-mediated cytotoxicity (ADCC) via its IgG1 Fc fragment binding to FcγRIIIa, thereby inhibiting tumor cell proliferation.